ESR1
Estrogen receptor
As of the edition of 20 October 2026, ESR1 (estrogen receptor, UniProt P03372) has 57 drugs tested at it and 78 companies on the list, 7 on route A and 18 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P03372
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 493
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Hormones; Nutrition and metabolism; Mental health; Nervous system
- Registered trials of its drugs
- 1,782
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 31 |
| Active | 7 |
| Went quiet | 8 |
| Stopped | 5 |
| Withdrawn from market | 2 |
| Status not established | 4 |
| Total | 57 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fulvestrant | Marketed | Phase 4 | none listed |
| Tamoxifen | Marketed | Phase 4 | none listed |
| Estradiol | Marketed | Phase 4 | Ends 2032 |
| Ethinyl estradiol | Marketed | Phase 4 | none listed |
| Clomiphene | Marketed | Phase 4 | none listed |
| Estrogen | Active | Phase 4 | none listed |
| Estrogens, conjugated | Marketed | Phase 4 | none listed |
| Raloxifene | Marketed | Phase 4 | none listed |
| Estradiol valerate | Marketed | Phase 4 | none listed |
| Elacestrant | Marketed | Phase 3 | Ends 2038 |
| Toremifene | Marketed | Phase 4 | none listed |
| Bazedoxifene | Marketed | Phase 4 | Ends 2027 |
12 of 57 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 18 |
| Engaged | 37 |
| Undetermined | 16 |
| Total on the list | 78 |
The other 75 companies at ESR1
In the product78 companies in all; 75 are not named here, and no score is.
See the 78 companies at ESR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.